Effects of walking and grounding on women with breast cancer
The Effect of Walking and Grounding on Pain Intensity, Fatigue Level, and Sleep Quality in Women With Breast Cancer
This study tests if walking and grounding techniques can help women with breast cancer feel less pain, reduce fatigue, and improve their sleep.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 54 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Ankara University Academic / other |
| Drugs / interventions | Transtuzumab, chemotherapy |
| Locations | 1 site (Ankara) |
| Trial ID | NCT06767059 on ClinicalTrials.gov |
What this trial studies
This trial investigates how walking and grounding techniques can influence pain intensity, fatigue, and sleep quality in women diagnosed with breast cancer. Grounding involves direct contact with the earth, which is believed to enhance circulation and improve overall well-being. Participants will be divided into groups to either engage in walking or grounding activities, with their health metrics monitored throughout the study. The goal is to determine if these interventions can alleviate common symptoms experienced by breast cancer patients.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older, diagnosed with primary breast cancer, currently undergoing specific chemotherapy treatments, and residing in Ankara.
Not a fit: Patients with open wounds, severe neuropathy, or other significant health issues that prevent walking may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method to reduce pain, fatigue, and improve sleep quality in breast cancer patients.
How similar studies have performed: While grounding techniques have shown promise in other contexts, this specific approach in breast cancer management is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older, * Can read and write and speak Turkish, * Diagnosed with primary breast cancer and know the diagnosis, * Volunteered to participate in the research, * Living in Ankara province, * Paclitaxel or Paclitaxel-Transtuzumab based chemotherapy treatment initiated, * Eastern Cooperative Oncology Group (ECOG) Scale 0 or 1, * NCI-CTCAE v5.0 Pain, fatigue and sleep toxicity grade 1 or 2, * You have a phone with an iOS or Android processor, Exclusion Criteria: * Open wounds or edema of the hands and feet, * NCI-CTCAE v5.0 motor and sensory peripheral neuropathy with toxicity grade 3,4 or 5, * People with a disability that would prevent them from walking, * Diagnosed cardiovascular and pulmonary disorders, * Diagnosed psychiatric illness, * Communication problems, * Bone metastases, * Bilateral mastectomies,
Where this trial is running
Ankara
- Gazi University Health Research and Application Center Gazi Hospital — Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Baise Bicav, MSc — Ankara University
- Study coordinator: Baise Bicav
- Email: baisebicav@gmail.com
- Phone: 05454702157
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.